Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort study
- PMID: 39735440
- PMCID: PMC11674434
- DOI: 10.1016/j.jncc.2024.08.001
Risk assessment and triage strategy of cervical cancer primary screening on HPV integration status: 5-year follow-up of a prospective cohort study
Abstract
Objective: We investigated the relation between man papillomavirus (HPV) integration status and the immediate risk of cervical intraepithelial neoplasia (CIN), as well as the triage strategy based on HPV integration test.
Methods: 4086 women aged 20 to 65 years in China were enrolled in 2015 for a prospective, population-based, clinical observational study to evaluate the triage performance of HPV integration. Cervical exfoliated cells were collected for HPV testing and cytologic test. If high-risk HPV was positive, HPV integration test was performed at baseline, 2-year and 5-year follow-up.
Results: At baseline, HPV integration was positively correlated with the severity of cervical pathology, ranging from 5.0% (15/301) in normal diagnosis, 6.9% (4/58) in CIN1, 31.0% (9/29) in CIN2, 70% (14/20) in CIN3, and 100% (2/2) in cervical cancer (P < 0.001). Compared with cytology, HPV integration exhibits comparable sensitivity and negative predictive value for the diagnosis of CIN3+, higher specificity (92.8% [90.2%-95.4%] vs. 75.5% [71.2%-79.8%], P < 0.001) and higher positive predictive value (36.4% [22.1%-50.6%] vs. 15.2% [8.5%-21.8%], P < 0.001). HPV integration testing strategy yielded a significantly lower colposcopy referral rate than cytology strategy (10.7% [44/410] vs. 27.3% [112/410], P < 0.001). The HPV integration-negative group exhibited the lowest immediate risk for CIN3+ (1.6%) and accounted for the largest proportion of the total population (89.3%), when compared with the normal cytology group (risk, 1.7%; proportion, 72.7%).
Conclusion: As a key molecular basis for the development of cervical cancer, HPV integration might be a promising triage strategy for HPV-positive patients.
Keywords: Cervical cancer screening; Cervical intraepithelial neoplasia; Colposcopy; HPV integration; Human papillomavirus.
© 2024 Chinese National Cancer Center. Published by Elsevier B.V.
Conflict of interest statement
Ding Ma and Zheng Hu are inventors of a patent (ZL201510217845.0) for the HPV integration test. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures


Similar articles
-
Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.Lancet Oncol. 2011 Sep;12(9):880-90. doi: 10.1016/S1470-2045(11)70188-7. Epub 2011 Aug 22. Lancet Oncol. 2011. PMID: 21865084 Clinical Trial.
-
Diagnostic accuracy of cervical cancer screening and screening-triage strategies among women living with HIV-1 in Burkina Faso and South Africa: A cohort study.PLoS Med. 2021 Mar 4;18(3):e1003528. doi: 10.1371/journal.pmed.1003528. eCollection 2021 Mar. PLoS Med. 2021. PMID: 33661957 Free PMC article.
-
Clinical Evaluation of Human Papillomavirus Screening With p16/Ki-67 Dual Stain Triage in a Large Organized Cervical Cancer Screening Program.JAMA Intern Med. 2019 Jul 1;179(7):881-888. doi: 10.1001/jamainternmed.2019.0306. JAMA Intern Med. 2019. PMID: 31081870 Free PMC article.
-
Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.JAMA Oncol. 2019 Feb 1;5(2):181-186. doi: 10.1001/jamaoncol.2018.4270. JAMA Oncol. 2019. PMID: 30325982 Free PMC article.
-
Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Vaccine. 2012. PMID: 23199969 Review.
Cited by
-
The biomarker potential of circPOLD1 and its binding protein YBX1 in cervical carcinogenesis.J Transl Med. 2025 May 4;23(1):506. doi: 10.1186/s12967-025-06494-3. J Transl Med. 2025. PMID: 40319271 Free PMC article.
-
Disruption Events in the HPV18 E1 and E2 Genes in Precancerous Cervical Lesions.Int J Mol Sci. 2025 Jul 20;26(14):6974. doi: 10.3390/ijms26146974. Int J Mol Sci. 2025. PMID: 40725221 Free PMC article.
References
-
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. - PubMed
-
- WHO guideline for screening and treatment of cervical precancer lesions for cervical cancer prevention (Second edition): WHO Guidelines. 2021 https://www.who.int/publications/i/item/9789240030824 Accessed April 20, 2024.
-
- Molina MA, Steenbergen RDM, Pumpe A, et al. HPV integration and cervical cancer: a failed evolutionary viral trait. Trends Mol Med. 2024;30(9):890–902. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials